

APPENDIX B
Serial No.: 09/640,838
Marked-Up Copies of the Claims

4. (Thrice Amended) The conjugate [according to claim 16] of Claim 15, wherein the chemotherapeutic agent is an antibiotic.

5. (Thrice Amended) The conjugate [according to claim 16] of Claim 15, wherein the chemotherapeutic agent is an antimetabolite.

15. (Reiterated) A conjugate useful for treating a disease selected from the group consisting of tumoral, infectious, and autoimmune disease in a subject comprising:

an active substance useful for treating said disease selected from the group consisting of a chemotherapeutic agent and a photoactive compound;

a native human serum albumin that is not regarded as exogenous by the subject; and

a linker linking said active substance to said albumin, wherein said linker can be cleaved intracellularly, and wherein said linker comprises an azo group.

17. (Twice Amended) The conjugate [according to] of Claim 15, wherein several active substances useful for treating said disease are linked to said albumin through one or more linkers.

18. (Twice Amended) The conjugate [according to] of Claim 15, wherein the linker has the following structure:



wherein:

R is an aromatic compound, and

Y is selected from the group consisting of C(O), S(O)₂, P(O)OH and As(O)OH.

20. (Twice Amended) The conjugate [according to] of Claim 15, wherein the conjugate comprises 4-aminophenylsulphonic acid or 4-aminophenylphosphonic acid and albumin.

21. (Twice Amended) The conjugate [according to] of Claim 15, wherein the conjugate comprises cytodine.

22. (Reiterated) The conjugate according to Claim 15, wherein the conjugate comprises tetracycline.

23. (Twice Amended) A process for the preparation of the conjugate [according to] of Claim 15, comprising binding an active substance selected from the group consisting of a chemotherapeutic agent and a photoactive compound useful for

treating a disease selected from the group consisting of tumoral, infectious, and autoimmune disease to a native human serum albumin that is not regarded as exogenous by the subject, by means of a linker containing an azo group.

24. (Twice Amended) A method of treating a disease selected from the group consisting of tumoral, infectious, and autoimmune disease, comprising administering [a] the conjugate [according to] of Claim 15 in an amount effective to ameliorate the symptoms of said disease.

25. (Twice Amended) The conjugate [according to] of Claim [16] 15, wherein several active substances are present.

26. (Twice Amended) The conjugate [according to] of Claim [16] 15, wherein the linker has the following structure:



wherein:

R is an aromatic compound, and

Y is a group selected from the group consisting of C(O), S(O)₂, P(O)OH and As(O)OH.

27. (Reiterated) The conjugate according to Claim 17, wherein the linker has the following structure:



wherein:

R is an aromatic compound, and

Y is a group selected from the group consisting of C(O), S(O)₂, P(O)OH and As(O)OH.

30. (Reiterated) The process of Claim 23, wherein said binding comprises the formation of an ester.

31. (Twice Amended) The conjugate of Claim 4, wherein the antibiotic comprises a tetracycline.

32. (Twice Amended) The conjugate of Claim 5, wherein the antimetabolite comprises a methotrexate.

33. (Twice Amended) The conjugate of Claim 5, wherein the antimetabolite comprises a sulfonamide.

34. (Twice Amended) The conjugate of Claim 5, wherein the antimetabolite comprises a nucleoside that inhibits the replication or transcription of a nucleic acid into which it is incorporated.

35. (Twice Amended) The conjugate of Claim 15, wherein the active substance comprises an acid group.

36. (Twice Amended) The conjugate of Claim 35, wherein the acid group is selected from the group consisting of $-\text{CO}_2\text{H}$, $-\text{SO}_3\text{H}$, $-\text{PO}_3\text{H}_2$, and $-\text{AsO}_3\text{H}_2$.

37. (Twice Amended) The conjugate of Claim 15, wherein the active substance is selected from the group consisting of 4-aminobenzoic acid, 2-aminobenzoic acid, 4-aminophenylsulfonic acid, 2-aminophenylsulfonic acid, 4-aminophenylphosphonic acid, 2-aminophenylphosphonic acid, 4-aminophenylarsonic acid, and 2-aminophenylarsonic acid.

38. (Twice Amended) The conjugate of Claim 15, wherein the active substance is selected from the group consisting of a deoxyuridine, a deoxycytidine, a cytosine arabinoside, a 5-fluorouracil, a 5-fluorodeoxyuridine, and an azidothymidine.

39. (Twice Amended) The conjugate of Claim [16] 15, wherein the photoactive compound comprises a porphyrine.

40. (Twice Amended) The conjugate of Claim [16] 15, wherein the photoactive compound is selected from the group consisting of a chlorine and a bacteriochlorine.

42. (Reiterated) The conjugate of Claim 18, 26 or 27, wherein the aromatic group comprises a phenylene.

43. (Reiterated) The conjugate of Claim 18, 26 or 27, wherein the aromatic group comprises a derivative of phenylene.